Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see how safe and tolerable, and to find the highest
or best dose, of an investigational combination of drugs called enasidenib and venetoclax, in
patients with relapsed (the cancer has come back) or refractory (the cancer does not respond
or have stopped responding to treatment) acute myeloid leukemia (AML, a type of blood
cancer). This study will also see how useful the combination of enasidenib and venetoclax is
in the treatment of patients with relapsed or refractory AML.